演題詳細

一般口演 / Oral Session

一般口演 26 (Oral Session 26) :CML:臨床TKIその他

print

日程
2013年10月11日(金)
時間
15:25 - 16:25
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
鳥本 悦宏 (Yoshihiro Torimoto):1
1:旭川医科大学病院 腫瘍センター
 
前へ戻る

Phase2 Study of Dasatinib for newly diagnosed chronic myeloid leukemia at Tohoku and Hokkaido

演題番号 : OS-1-130

山口 公平 (Kohei Yamaguchi):1、村井 一範 (Kazunori Murai):2,9、伊藤 薫樹 (Shigeki Ito):2,9、赤木 智昭 (Tomoaki Akagi):1,9、小川 一英 (Kazuei Ogawa):4,9、目黒 邦昭 (Kuniaki Meguro):3,9、猪股 美津恵 (Mitsue Inomata):3,9、渡部 玲子 (Reiko Watanabe):5,9、宮城島 拓人 (Takuto Miyagishima):6,9、若狭 健太郎 (Kentaro Wakasa):7,9、進藤 基博 (Motohiro Shindo):8,9、筑紫 泰彦 (Yasuhiko Tsukushi):2,9、石田 陽治 (Yoji Ishida):2,9

1:Dept. of Hematology,Aomori Prefectural Central Hospital,Japan、2:Dept. of Hematology and Oncology,Iwate Medical University,Japan、3:Dept. of Hematology,National Hospital Organization Sendai Medical Center,Japan、4:Dept. of Cardiology and Hematology,Fukushima Medical University,Japan、5:Dept. of Hematology,Saitama Medical Center,Saitama Medical University,Japan、6:Kushiro Rosai Hospital,Japan、7:4th. Dept. Int. Med.,Obihiro Kosei General Hospital,Japan、8:Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical University,Japan、9:Inter-Michinoku Dasatinib Study Group (IMIDAS)

 

Introduction:We conducted a phase 2 study to evaluate the efficacy and safety of dasatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) in the Tohoku and Hokkaido region of Japan. Methods:Patients received dasatinib 100mg once daily. Treatment was continued until disease progression or unacceptable toxicity. Primary end point was the rate of major molecular response(MMR) at 12 months. MMR defined as a BCR-ABL transcript level of 0.1% or lower on the International scale by means of a real-time quantitative reverse-transcriptase-polymerase-chain-reaction(RT-PCR) in peripheral blood. Secondary end points were the rate of complete cytogenetic response(CCyR) by 12 months,the rate of complete molecular response(CMR) by 12 months and safety of dasatinib. Results:A total of 74 patients with newly diagnosed chronic-phase CML were assessed for eligibility between June 2010 and March 2013.All of these patients started dasatinib 100mg once daily.MMR by 12 months were achieved in 27 patients(90.0%) among the 30 patients receiving dasatinib more than 12 months.CMR by 12 months were achieved in 18 patients(60.0%) among patients above-mentioned. Conclusion:Dasatinib is an effective agent for patients with the newly diagnosed chronic-phase CML in Japanese patients.

前へ戻る